Janus Kinase Inhibition for Graft-Versus-Host Disease:Current Status and Future Prospects: Current Status and Future ProspectsMannina D, Kröger NDRUGS. Metolazone for severe dilated cardiomyopathy refractory to conventional therapyKröger N, Szuba J, Buhl C, Pompecki R, Frenzel HLANCET. Endothelial complications after allogeneic stem cell transplantation in patients with pretransplant resolved COVID-19Niederwieser C, Weber B, Reichard M, Gagelmann N, Ajib S, Schlipfenbacher V, Zeng Z, Lang F, Janson D, Wolschke C, Ayuk F, Bug G, Kröger NBONE MARROW TRANSPL. JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasmsParampalli Yajnanarayana S, Stübig T, Cornez I, Alchalby H, Schönberg K, Rudolph J, Triviai I, Wolschke C, Heine A, Brossart P, Kröger N, Wolf DBRIT J HAEMATOL. Evaluation of six different types of sequential conditioning regimens for allogeneic stem cell transplantation in relapsed/refractory acute myelogenous leukemia - a study of the Acute Leukemia Working Party of the EBMTHeinicke T, Labopin M, Polge E, Stelljes M, Ganser A, Tischer J, Brecht A, Kröger N, Beelen D, Scheid C, Bethge W, Dreger P, Bunjes D, Wagner E, Platzbecker U, Savani B, Nagler A, Mohty MLEUKEMIA LYMPHOMA. Minimal residual disease following allogeneic hematopoietic stem cell transplantation.Kröger N, Miyamura K, Bishop MBIOL BLOOD MARROW TR. Circulating CD34(+) cells as prognostic and follow-up marker in patients with myelofibrosis undergoing allo-SCT.Alchalby H, Lioznov M, Fritzsche-Friedland U, Badbaran A, Zabelina T, Bacher U, Stübig T, Ayuketang Ayuk F, Zander A, Kröger NBONE MARROW TRANSPL. 2014;92(3):189-94. Prevention and Treatment of Relapse by DrugsKroger N2019. 2017;52(9):1233-1240. Relapse of postpolycythemia myelofibrosis after allogeneic stem cell transplantation in a polycythemic phase: successful treatment with donor lymphocyte infusion directed by quantitative PCR test for V617F-JAK2 mutation.Benjamini O, Koren-Michowitz M, Amariglio N, Kröger N, Nagler A, Shimoni ALEUKEMIA. Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantationPassweg J, Baldomero H, Peters C, Gaspar H, Cesaro S, Dreger P, Duarte R, Falkenburg J, Farge-Bancel D, Gennery A, Halter J, Kröger N, Lanza F, Marsh J, Mohty M, Sureda A, Velardi A, Madrigal ABONE MARROW TRANSPL. 2022;57(3):343-346. Diagnostic performance of whole-body MRI for the detection of persistent or relapsing disease in multiple myeloma after stem cell transplantation.Bannas P, Hentschel H, Bley T, Treszl A, Zu Eulenburg C, Derlin T, Yamamura J, Adam G, Stübig T, Kröger N, Weber CEUR RADIOL. 2021;21(12):831-840. An early-biomarker algorithm predicts lethal graft-versus-host disease and survivalHartwell M, Özbek U, Holler E, Renteria A, Major-Monfried H, Reddy P, Aziz M, Hogan W, Ayuk F, Efebera Y, Hexner E, Bunworasate U, Qayed M, Ordemann R, Wölfl M, Mielke S, Pawarode A, Chen Y, Devine S, Harris A, Jagasia M, Kitko C, Litzow M, Kröger N, Locatelli F, Morales G, Nakamura R, Reshef R, Rösler W, Weber D, Wudhikarn K, Yanik G, Levine J, Ferrara JJCI INSIGHT. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age >69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationRingdén O, Boumendil A, Labopin M, Canaani J, Beelen D, Ehninger G, Niederwieser D, Finke J, Stelljes M, Gerbitz A, Ganser A, Kröger N, Kantz L, Brecht A, Savani B, Sadeghi B, Mohty M, Nagler ABIOL BLOOD MARROW TR. HLA-mismatched unrelated donors as an alternative graft source for allogeneic stem cell transplantation after antithymocyte globulin-containing conditioning regimen.Kröger N, Zabelina T, Binder T, Ayuketang Ayuk F, Bacher U, Amtsfeld G, Lellek H, Schrum J, Erttmann R, Eiermann T, Zander ABIOL BLOOD MARROW TR. Which patients with myelofibrosis should receive ruxolitinib therapy? 2014;50(2):209-215. MAGIC biomarkers predict long term outcomes for steroid-resistant acute GVHDMajor-Monfried H, Renteria A, Pawarode A, Reddy P, Ayuk F, Holler E, Efebera Y, Hogan W, Wölfl M, Qayed M, Hexner E, Wudhikarn K, Ordemann R, Young R, Shah J, Hartwell M, Chaudhry M, Aziz M, Etra A, Yanik G, Kröger N, Weber D, Chen Y, Nakamura R, Rösler W, Kitko C, Harris A, Pulsipher M, Reshef R, Kowalyk S, Morales G, Torres I, Özbek U, Ferrara J, Levine JBLOOD. 2017;102(1):160-167. Conditioning-based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991-2012) on behalf of EBMT CMWPHayden P, Iacobelli S, Pérez-Simón J, van Biezen A, Minnema M, Niittyvuopio R, Schönland S, Meijer E, Blaise D, Milpied N, Márquez-Malaver F, Veelken J, Maertens J, Michallet M, Cammenga J, N'Guyen S, Niederwieser D, Hunault-Berger M, Bourhis J, Passweg J, Bermudez A, Chalandon Y, Yakoub-Agha I, Garderet L, Kröger NEUR J HAEMATOL. Klinik-Bewertungen für Universitätsklinikum Hamburg Eppendorf (UKE) Onkologie, Martinistraße 52,. 2018;24(7):1372-1378. Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantationvan Gelder M, de Wreede L, Bornhäuser M, Niederwieser D, Karas M, Anderson N, Gramatzki M, Dreger P, Michallet M, Petersen E, Bunjes D, Potter M, Beelen D, Cornelissen J, Yakoub-Agha I, Russell N, Finke J, Schoemans H, Vitek A, Urbano-Ispízua Á, Blaise D, Volin L, Chevallier P, Caballero D, Putter H, van Biezen A, Henseler A, Schönland S, Kröger N, Schetelig JBONE MARROW TRANSPL. Steroid-refractory chronic graft-versus-host disease: treatment options and patient managementWolff D, Fatobene G, Rocha V, Kröger N, Flowers MBONE MARROW TRANSPL. 2017;23(7):1193-1202. 2015;10(3):e0119595. 2021;56(8):1944-1952. 2022;6(10):. Allogeneic hematopoietic stem cell transplantation for adult HLH: a retrospective study by the chronic malignancies and inborn errors working parties of EBMTMachowicz R, Suarez F, Wiktor-Jedrzejczak W, Eikema D, de Wreede L, Blok H, Isaksson C, Einsele H, Poiré X, van Dorp S, Nikolousis E, Johansson J, Kobbe G, Zecca M, Arnold R, Gerbitz A, Finke J, Díez-Martín J, Bonifazi F, McQuaker G, Lenhoff S, Rohrlich P, Theobald M, Ljungman P, Collin M, Albert M, Ehninger G, Carlson K, Halaburda K, Lehmberg K, Schönland S, Yakoub-Agha I, Gennery A, Lankester A, Kröger NBONE MARROW TRANSPL. Hematopoietic stem cell transplantation for adolescents and adults with inborn errors of immunity: an EBMT IEWP studyAlbert M, Sirait T, Eikema D, Bakunina K, Wehr C, Suarez F, Fox M, Mahlaoui N, Gennery A, Lankester A, Beier R, Bernardo M, Bigley V, Lindemans C, Burns S, Carpenter B, Dybko J, Güngör T, Hauck F, Lum S, Balashov D, Meisel R, Moshous D, Schulz A, Speckmann C, Slatter M, Strahm B, Uckan-Cetinkaya D, Meyts I, Vallée T, Wynn R, Neven B, Morris E, Aiuti A, Maschan A, Aljurf M, Gedde-Dahl T, Gurman G, Bordon V, Kriván G, Locatelli F, Porta F, Valcárcel D, Beguin Y, Faraci M, Kröger N, Kulagin A, Shaw P, Veelken J, Diaz de Heredia C, Fagioli F, Felber M, Gruhn B, Holter W, Rössig C, Sedlacek P, Apperley J, Ayas M, Bodova I, Choi G, Cornelissen J, Sirvent A, Khan A, Kupesiz A, Lenhoff S, Ozdogu H, von der Weid N, Rovira M, Schots R, Vinh DBLOOD. Reduced-intensity conditioning followed by allogeneic hematopoietic stem cell transplantation in myelofibrosis.Alchalby H, Kröger NCURR HEMATOL MALIG R. 2010;5(2):53-61. Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert ConsensusBuske C, Dreyling M, Alvarez-Larrán A, Apperley J, Arcaini L, Besson C, Bullinger L, Corradini P, Giovanni Della Porta M, Dimopoulos M, D'Sa S, Eich H, Foà R, Ghia P, da Silva M, Gribben J, Hajek R, Harrison C, Heuser M, Kiesewetter B, Kiladjian J, Kröger N, Moreau P, Passweg J, Peyvandi F, Rea D, Ribera J, Robak T, San-Miguel J, Santini V, Sanz G, Sonneveld P, von Lilienfeld-Toal M, Wendtner C, Pentheroudakis G, Passamonti FESMO OPEN. Second allogeneic stem cell transplantation in myeloid malignancies.Hartwig M, Ocheni S, Asenova S, Wiedemann B, Zabelina T, Ayuketang Ayuk F, Kabisch H, Erttmann R, Kröger N, Zander A, Bacher UACTA HAEMATOL-BASEL. Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.Oyekunle A, Zander A, Binder M, Ayuketang F, Zabelina T, Christopeit M, Stübig T, Alchalby H, Schafhausen P, Lellek H, Wolschke C, Müller I, Bacher U, Kröger NANN HEMATOL. Current Challenges in Stem Cell Transplantation in MyelofibrosisKröger NCURR HEMATOL MALIG R. 2015;10(4):344-50. Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma.Kröger N, Badbaran A, Lioznov M, Schwartz S, Zeschke S, Hildebrandt Y, Ayuketang Ayuk F, Atanackovic D, Schilling G, Zabelina T, Bacher U, Klyuchnikov E, Shimoni A, Nagler A, Corradini P, Fehse B, Zander AEXP HEMATOL. Low frequency of calreticulin mutations in MDS patientsHeuser M, Panagiota V, Koenecke C, Fehse B, Alchalby H, Badbaran A, Shahswar R, Stadler M, Eder M, Göhring G, Trummer A, Schroeder T, Kobbe G, Thiede C, Platzbecker U, Schlegelberger B, Kroeger N, Ganser A, Thol FLEUKEMIA. 2023;108(2):655-656. Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trialMinnema M, Nasserinejad K, Hazenberg B, Hegenbart U, Vlummens P, Ypma P, Kröger N, Wu K, Kersten M, Schaafsma M, Croockewit S, de Waal E, Zweegman S, Tick L, Broijl A, Koene H, Bos G, Sonneveld P, Schönland SHAEMATOLOGICA. Medizinische Klinik, UKE: Palliativversorgung als Teil der onkologischen Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation.Schmid C, Labopin M, Nagler A, Niederwieser D, Castagna L, Tabrizi R, Stadler M, Kuball J, Cornelissen J, Vorlicek J, Socié G, Falda M, Vindeløv L, Ljungman P, Jackson G, Kröger N, Rank A, Polge E, Rocha V, Mohty M, Blood A, Transplantation MBLOOD. 2015;50(8):1037-56. Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMTBrissot E, Labopin M, Ehninger G, Stelljes M, Brecht A, Ganser A, Tischer J, Kröger N, Afanasyev B, Finke J, Elmaagacli A, Einsele H, Mohty M, Nagler AHAEMATOLOGICA. SETBP1 mutation analysis in 944 patients with MDS and AMLThol F, Suchanek K, Koenecke C, Stadler M, Platzbecker U, Thiede C, Schroeder T, Kobbe G, Kade S, Löffeld P, Banihosseini S, Bug G, Ottmann O, Hofmann W, Krauter J, Kröger N, Ganser A, Heuser MLEUKEMIA. 2014;20(9):1448-50. 18F-FDG PET/CT for Detection of Leukemic Transformation in MyelofibrosisDerlin T, Clauditz T, Kröger NCLIN NUCL MED. Moderne Bildgebungsverfahren beim Multiplen MyelomBannas P, Kröger N, Adam G, Derlin TROFO-FORTSCHR RONTG. 2017;130(3):241-242. 2016;17(9):E1515. Zu den Organkrebszentren Sprechstunden In search of the optimal platform for Post-Allogeneic SCT immunotherapy in relapsed multiple myeloma: a systematic reviewOostvogels R, Uniken Venema S, de Witte M, Raymakers R, Kuball J, Kröger N, Minnema MBONE MARROW TRANSPL. 2015;171(5):752-62. 2011;17(3):374-83. 2002;87(3):299-305. 2021;56(10):2617. 2009. 2009;94(3):439-441. 2016;374(1):43-53. 1991;86(6):305-8, 332. 2011;2011:302145. Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia - A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMTvan Gelder M, Ziagkos D, de Wreede L, van Biezen A, Dreger P, Gramatzki M, Stelljes M, Andersen N, Schaap N, Vitek A, Beelen D, Lindström V, Finke J, Passweg J, Eder M, Machaczka M, Delgado J, Krüger W, Raida L, Socié G, Jindra P, Afanasyev B, Wagner E, Chalandon Y, Henseler A, Schoenland S, Kröger N, Schetelig JCL LYMPH MYELOM LEUK. Results of a European Group for Blood and Marrow Transplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxideMorris C, de Wreede L, Scholten M, Brand R, van Biezen A, Sureda A, Dickmeiss E, Trneny M, Apperley J, Chiusolo P, van Imhoff G, Lenhoff S, Martinelli G, Hentrich M, Pabst T, Onida F, Quinn M, Kröger N, de Witte T, Ruutu TTRANSFUSION. 2022;57(7):1116-1123. Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working PartyRobinson S, Boumendil A, Finel H, Peggs K, Chevallier P, Sierra J, Finke J, Poiré X, Maillard N, Milpied N, Yakoub-Agha I, Koh M, Kröger N, Nagler A, Koc Y, Dietrich S, Montoto S, Dreger PBONE MARROW TRANSPL. Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosisAlchalby H, Yunus D, Zabelina T, Ayuketang F, Kröger NBONE MARROW TRANSPL. State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019: allogeneic stem cell transplantation for myelofibrosis in 2019McLornan D, Yakoub-Agha I, Robin M, Chalandon Y, Harrison C, Kroger NHAEMATOLOGICA. 2013;121(12):2324-35. Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working PartiesDreger P, Michallet M, Bosman P, Dietrich S, Sobh M, Boumendil A, Nagler A, Scheid C, Cornelissen J, Niederwieser D, Müller L, Vandenberghe E, Scortechini I, Schoemans H, Andersen N, Finke J, Russo D, Ljungman P, Passweg J, van Gelder M, Durakovic N, Labussiere-Wallet H, Berg T, Wulf G, Bethge W, Bunjes D, Stilgenbauer S, Canepari M, Schaap M, Fox C, Kröger N, Montoto S, Schetelig JBONE MARROW TRANSPL. Predictive Factors for Outcome of First Allogeneic Transplant for Elderly Patients With Acute Lymphoblastic LeukemiaBazarbachi A, Labopin M, Kröger N, Brecht A, Blaise D, Clausen J, Fanin R, Einsele H, Cavanna L, Itäla-Remes M, Bulabois C, Kündgen L, Martin H, Schmid C, Wagner-Drouet E, Alakel N, Bazarbachi A, Savani B, Nagler A, Mohty MCL LYMPH MYELOM LEUK. Die wichtigsten onkologischen Spitzenzentren Charité Comprehensive Cancer Center Berlin Die Klinik arbeitet eng mit verschiedenen Spezialisten zusammen, die aus unterschiedlichen Fachrichtungen stammen. 2021;56(12):2876-2881. 2017;2(3):e89798. Bewertung von 15 minütigen Abschlussreferaten und Diskussion zu allg. 2009;88(5):401-404. Improving allogeneic stem cell transplantation in myelofibrosisGagelmann N, Kroger NINT J HEMATOL. Radiotherapy after high-dose chemotherapy and peripheral blood stem cell support in high-risk breast cancer.Hoeller U, Juergen H, Kröger N, Krueger W, Jaenicke F, Alberti WINT J RADIAT ONCOL. 2021;56(7):1593-1602. 2009. 2021;192(6):e151-e154. 2022;107(5):1054-1063. 2021;56(3):622-634. Role of Age and Hematopoietic Cell Transplantation-Specific Comorbidity Index in Myelodysplastic Patients Undergoing an Allotransplant: A Retrospective Study from the Chronic Malignancies Working Party of the European Group for Blood and Marrow TransplantationCarré M, Porcher R, Finke J, Ehninger G, Koster L, Beelen D, Ganser A, Volin L, Lozano S, Friis L, Michallet M, Tischer J, Olavarria E, Cascon M, Iacobelli S, Koc Y, Jindra P, Arat M, de Witte T, Yakoub Agha I, Kröger N, Robin MBIOL BLOOD MARROW TR. 2020;26(7):e167-e170. Correlation of somatic mutations with outcome after FLAMSA-busulfan sequential conditioning and allogeneic stem cell transplantation in patients with MDSChristopeit M, Badbaran A, Alawi M, Zabelina T, Zeck G, Wolschke C, Ayuketang F, Kröger NEUR J HAEMATOL. 2015;2(12):2101-9. 2015;125(21):3347-3350. UNI-MED Verlag: 47-56. 2013;19(3):398-404. Endogenous retrovirus induces leukemia in a xenograft mouse model for primary myelofibrosisTriviai I, Ziegler M, Bergholz U, Oler A, Stübig T, Prassolov V, Fehse B, Kozak C, Kröger N, Stocking CP NATL ACAD SCI USA. Longitudinal analysis of tetanus- and influenza-specific IgG antibodies in myeloma patients.Kobold S, Luetkens T, Bartels B, Cao Y, Hildebrandt Y, Sezer O, Reinhard H, Templin J, Bartels K, Lajmi N, Haag F, Bokemeyer C, Kröger N, Atanackovic DClin Dev Immunol. Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation.Ayuketang Ayuk F, Diyachenko G, Zabelina T, Wolschke C, Fehse B, Bacher U, Erttmann R, Kröger N, Zander ABIOL BLOOD MARROW TR. 2006;76(1):9-17. 2016;57(6):1256-1268. The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients.Cao Y, Luetkens T, Kobold S, Hildebrandt Y, Gordic M, Lajmi N, Meyer S, Bartels K, Zander A, Bokemeyer C, Kröger N, Atanackovic DEXP HEMATOL. Peritransplantation Ruxolitinib Prevents Acute Graft-versus-Host Disease in Patients with Myelofibrosis Undergoing Allogenic Stem Cell TransplantationKröger N, Shahnaz Syed Abd Kadir S, Zabelina T, Badbaran A, Christopeit M, Ayuk F, Wolschke CBIOL BLOOD MARROW TR. Third International workshop on the biology, prevention, and treatment of relapse after stem cell transplantationKröger N, Bishop M, Giralt S, Wayne ABONE MARROW TRANSPL. 2014;28(11):2235-40. Coinhibitory Molecule PD-1 as a Therapeutic Target in the Microenvironment of Multiple MyelomaAtanackovic D, Luetkens T, Radhakrishnan S, Kroger NCURR CANCER DRUG TAR. Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantationBattipaglia G, Labopin M, Kröger N, Vitek A, Afanasyev B, Hilgendorf I, Schetelig J, Ganser A, Blaise D, Itälä-Remes M, Passweg J, Bonifazi F, Finke J, Ruggeri A, Nagler A, Mohty MBLOOD. Nur wie das gehen soll, hat den Angehörigen niemand gesagt. 2022;28(6):337.e1-337.e10. Comparative diagnostic performance of ¹⁸F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantationDerlin T, Peldschus K, Münster S, Bannas P, Herrmann J, Stübig T, Habermann C, Adam G, Kröger N, Weber CEUR RADIOL. Dualism of mixed chimerism between hematopoiesis and stroma in chronic idiopathic myelofibrosis after allogeneic stem cell transplantation.Thiele J, Varus E, Siebolts U, Kvasnicka H, Wickenhauser C, Metz K, Beelen D, Ditschkowski M, Zander A, Kröger NHISTOL HISTOPATHOL. JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasmsRao T, Hansen N, Hilfiker J, Rai S, Majewska J, Leković D, Gezer D, Andina N, Galli S, Cassel T, Geier F, Delezie J, Nienhold R, Hao-Shen H, Beisel C, Di Palma S, Dimeloe S, Trebicka J, Wolf D, Gassmann M, Fan T, Lane A, Handschin C, Dirnhofer S, Kröger N, Hess C, Radimerski T, Koschmieder S, Čokić V, Skoda RBLOOD. 2011;126(1):30-39. Unrelated donor stem cell transplantation in acquired severe aplastic anemia: a systematic review.Peinemann F, Grouven U, Kröger N, Pittler M, Zschorlich B, Lange SHAEMATOLOGICA. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors.Ayuketang Ayuk F, Diyachenko G, Zabelina T, Panse J, Wolschke C, Eiermann T, Binder T, Fehse B, Erttmann R, Kabisch H, Bacher U, Kröger N, Zander AEXP HEMATOL.